Skip to main content
森萱医药 logo

森萱医药 — Investor Relations & Filings

Ticker · 920946 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2026-05-06 Investor Presentation
Country CN China
Listing Beijing Stock Exchange 920946

About 森萱医药

https://www.senxuan.cn/

Jiangsu Senxuan Pharmaceutical Co., Ltd. specializes in the research, development, and production of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and specialized fine chemicals. The company’s product portfolio includes key intermediates for antiviral medications, such as those used in the treatment of HIV, and anticonvulsant agents like Primidone. Additionally, it produces high-purity chemical solvents including 1,4-dioxane and 1,3-dioxolane for diverse industrial applications. Senxuan Pharmaceutical maintains a focus on advanced chemical synthesis and large-scale manufacturing capabilities, adhering to international quality standards to support the global life sciences and chemical sectors. Its operations are characterized by a commitment to technical innovation and the supply of critical chemical building blocks for complex therapeutic formulations.

Recent filings

Filing Released Lang Actions
2025年年度报告业绩说明会预告公告
Investor Presentation Classification · 90% confidence The document is a notice announcing a scheduled performance explanation meeting related to the company's 2025 Annual Report. It references the already published 2025 Annual Report and its summary, and invites investors to participate in a webcast meeting to discuss the report. The document itself does not contain the full annual report or detailed financial data, but rather serves as an announcement for the upcoming investor presentation event. The document length is short (1045 characters), and it explicitly states the report has been disclosed previously. Therefore, this document is best classified as an Investor Presentation (IP) announcement or related material, but since it is announcing the meeting rather than providing the presentation itself, it fits best under Investor Presentation (IP) category as it focuses on financials and strategy discussion with investors.
2026-05-06 Chinese
关于召开2025年年度股东会通知公告（提供网络投票）
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2025 Annual General Meeting (AGM) of 江苏森萱医药股份有限公司. It includes information about the meeting date, voting methods (including online voting), agenda items to be discussed and voted on (such as the 2025 annual report, board reports, dividend plans, director elections, and remuneration matters), registration procedures, and proxy forms. The document does not contain the actual annual report or financial statements but rather the announcement and logistical details for the upcoming AGM. The document length is 4157 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2026-04-21 Chinese
第四届董事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 13th meeting of the 4th Board of Directors of Jiangsu Senxuan Pharmaceutical Co., Ltd. It includes voting results on various reports and proposals such as the 2025 annual general manager work report, board work report, independent directors' reports, audit reports, financial statements, internal control reports, remuneration, and nominations for independent directors. The document repeatedly references that the detailed reports are disclosed separately on the Beijing Stock Exchange information disclosure platform with specific announcement numbers. The document itself does not contain the full reports or financial statements but summarizes the board meeting decisions and voting outcomes. This type of document is a Board/Management Information announcement, as it reports on board meeting resolutions and management decisions rather than the full annual report or audit report itself. The document length (7940 characters) and content confirm it is not a brief notice or a simple announcement of report publication but a comprehensive board meeting resolution announcement. Therefore, the appropriate classification is MANG (Board/Management Information).
2026-04-21 Chinese
2025年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2025年度内部控制自我评价报告' which translates to '2025 Internal Control Self-Evaluation Report'. It is issued by the company's board and discusses the evaluation of the company's internal control effectiveness as of December 31, 2025. The content includes detailed descriptions of internal control systems, governance, risk management, and control deficiencies related to financial and non-financial reporting. It does not contain financial statements or earnings data but focuses on internal control evaluation and compliance with regulatory standards. This type of document is a standalone audit-related report focusing on internal control evaluation, which fits the category of Audit Report / Information (AR). The document length is 7449 characters, sufficient for a substantive report rather than a brief announcement. Therefore, the appropriate classification is AR with high confidence. FY 2025
2026-04-21 Chinese
2025年度董事会工作报告
Management Reports Classification · 95% confidence The document is titled '2025年度董事会工作报告' which translates to '2025 Annual Board of Directors Work Report'. It contains detailed financial data for the year 2025, including profitability, solvency, operational and growth metrics. It also extensively discusses the board's activities, governance, internal controls, compliance, investor relations, dividend policy, independent directors' duties, and future plans. The document is comprehensive and includes substantive financial data and management discussion, typical of a Management Reports (MDA) filing. It is not a full Annual Report (10-K) as it lacks the full financial statements and audit opinions, nor is it a simple announcement or certification. The length (5450 characters) and content indicate it is a detailed management report on the board's work and company performance for the year. Therefore, the appropriate classification is Management Reports (MDA).
2026-04-21 Chinese
关于向商业银行申请授信并贷款的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Jiangsu Senxuan Pharmaceutical Co., Ltd. regarding the company's plan to apply for credit and loans from commercial banks. It details the loan amount, authorization for company representatives to handle loan procedures, and mentions the board meeting where the proposal was approved and that it will be submitted to the annual shareholders meeting for approval. The document is short (698 characters) and focuses on financing activities, specifically loan application and credit facilities. It does not contain financial statements or detailed financial results, nor is it a report or presentation. This fits the definition of a Capital/Financing Update (CAP).
2026-04-21 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.